Therefore, PR-based strategies in CF (as administration of cystamine or genetic restoration of BECN1) may have a dual effect, as they reduce lung inflammation while rescuing a functional mutant CFTR to the epithelial surface. This evidence concerns the gene CFTR and cystic fibrosis.